Merck KGaA, Darmstadt, Germany Receives Approval (Updated Registration) for Cladribine Tablets in Australia
(WorldNews Germany)

About Cladribine Tablets Cladribine Tablets is an investigational short-course oral therapy that is thought to selectively target lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). Cladribine Tablets is currently under clinical investigation and not yet approved for any use in the United States. In August 2017, the European Commission (EC) granted marketing authorization for Cladribine Tablets, marketed as MAVENCLAD, for the treatment of adult patients with highly active relapsing forms of multiple sclerosis (RMS) as defined by clinical or imaging features in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. In...